Open-trial on the Prevention of Chronic Migraines With the CEFALY Device
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Anschutz Medical Campus - Department of Neurology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with a history of chronic migraine meeting the diagnostic criteria listed in ICHD-III beta (2013) section 1, migraine (1), with the exception of ''complicated migraine'' (i.e., hemiplegic migraine, migraine with brainstem aura, ophthalmoplegic migraine-recurrent painful ophthalmoplegic neuropathy, migrainous infarction) will be enrolled. They are required during baseline to have ≥15 headache days with each day consisting of ≥4 hours of continuous headache and with ≥50% of days being migraine or probable migraine days; and ≥4 distinct headache episodes, each lasting ≥4 hours.
Both patients with or without acute medication overuse (medication overuse headache - MOH) will be recruited
Exclusion Criteria:
- Women: Pregnant, lactating or <6 months post partum
- For patients already on treatment with medications in the following classes: antihypertensives, antidepressants, antiepileptics, no dose change of those medications is allowed for at least 3 months before start of baseline and during the entire study period.
- For patients treated with Botox, no injection within 4 months before start of baseline or during the study.
- Diagnosis of other primary or secondary headache disorders, except of Medication Overuse Headache
- A Beck Depression Inventory score of >24 at baseline
- Psychiatric disorders that could have interfered with study participation
- Intolerance to supraorbital neurostimulation that makes the treatment not applicable (test of nociceptive threshold with specific Cefaly program)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Active
Daily trigeminal nerve stimulation session of 20 minutes with CEFALY
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in Frequency of Headache Days
Time Frame: End of baseline period and end of 12 weeks treatment period
|
Mean change in frequency of headache days (defined as a day with at least one headache episode, which is a patient-reported headache with pain) between the 28-day baseline and the 28-day period ending with week 12 of treatment.
|
End of baseline period and end of 12 weeks treatment period
|
|
Change From Baseline in Acute Medication Intake
Time Frame: End of baseline period and end of 12 weeks treatment period
|
Overall acute headache pain medication use (all categories) mean change between the 28-day baseline and the 28-day period ending with week 12 of treatment.
|
End of baseline period and end of 12 weeks treatment period
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Frequency of Migraine Days
Time Frame: End of baseline period and end of 12 weeks treatment period
|
Mean change in frequency of migraine days (any headache day is a migraine day, unless the pain intensity = 1 and there is no intake of acute anti-migraine medication) between the 28-day baseline and the 28-day period ending with week 12 of treatment.
|
End of baseline period and end of 12 weeks treatment period
|
|
Change in Frequency of Moderate/Severe Headache Days
Time Frame: End of baseline period and end of 12 weeks treatment period
|
Mean change in frequency of moderate/severe headache days (defined as a headache day with at least one headache episode with intensity = 2 or 3) between the 28-day baseline and the 28-day period ending with week 12 of treatment.
|
End of baseline period and end of 12 weeks treatment period
|
|
Change in Monthly Cumulative Headache Hours
Time Frame: End of baseline period and end of 12 weeks treatment period
|
Mean change in monthly cumulative headache hours on headache days between the 28-day baseline and the 28-day period ending with week 12 of treatment.
|
End of baseline period and end of 12 weeks treatment period
|
|
Change in Frequency of Headache Episodes
Time Frame: End of baseline period and end of 12 weeks treatment period
|
Mean change in frequency of headache episodes (defined as a patient-reported headache with pain) between the 28-day baseline and the 28-day period ending with week 12 of treatment.
|
End of baseline period and end of 12 weeks treatment period
|
|
50% Responder Rate for Migraine Days
Time Frame: End of the 12 weeks treatment period
|
Number of subjects who observe a 50% reduction in the frequency of their migraine days between the 28-day baseline and the 28-day period ending with week 12 of treatment.
|
End of the 12 weeks treatment period
|
|
Change in the Average Headache Intensity
Time Frame: End of baseline period and end of 12 weeks treatment period
|
Mean change in the average headache intensity between the 28-day baseline and the 28-day period ending with week 12 of treatment.
Headache intensity is defined on a scale from 0 (no pain) to 3 (maximum pain).
|
End of baseline period and end of 12 weeks treatment period
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Marius Birlea, MD, Department of Neurology, University of Colorado Anschutz Medical Campus
- Study Director: Pierre Rigaux, Cefaly Technology
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 50207
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.